Clinical Study onQishen Erlian Decoction Combined with Entecavir for Patients with Liver Fibrosis of Hepatitis B
10.3969/j.issn.1005-5304.2016.11.008
- VernacularTitle:芪参二莲汤联合恩替卡韦治疗乙型肝炎肝纤维化临床研究
- Author:
Xingxing YUAN
;
Bingyu WANG
;
Lei YANG
;
Lei GUO
;
Changfa LIU
;
Yali ZHANG
- Publication Type:Journal Article
- Keywords:
Qishen Erlian Decoction;
chronic hepatitis B;
liver fibrosis;
clinical efficacy
- From:
Chinese Journal of Information on Traditional Chinese Medicine
2016;23(11):29-33
- CountryChina
- Language:Chinese
-
Abstract:
Objective To observe the clinical efficacy ofQishen Erlian Decoction combined with entecavir for patients with liver fibrosis of hepatitis B.MethodsTotally 74 patients were divided into treatment group (38 cases) and control group (36 cases). The control group was given entecavir, while treatment group was given Qishen Erlian Decoction combined with entecavir, 48 weeks for 1 course. Entecavir was given to both groups after treatment, and two groups were followed up for 24 weeks. The liver function, DNA-HBV, serum TGF-β1, BMP-7, liver fibrosis indexes and clinical symptom changes of the two groups were observed.Results 3 cases were excluded and 3 cases were lost during follow-up in treatment group; 6 cases were lost during follow-up in the control group. Liver function and HBV-DNA in 12, 24, 36, 48 weeks and 24 weeks in follow-up were significantly lower than those pre-treatment (P<0.01) in the treatment group, and were significantly better than those in the control group (P<0.01). TGF-β1 decreased (P<0.05), BMP-7 increased (P<0.01), and the ratio of TGF-β1/BMP-7 decreased (P<0.01) in both groups after treatment. There was significant difference between the two groups (P<0.05). HA, LN, PCⅢ,Ⅳ-C, and FS decreased significantly in treatment group after treatment and in the follow-up (P<0.01), fatigue, discomfort in liver region, disgust oil and anorexia were improved (P<0.05), the difference was significant compared with control group (P<0.05).Conclusion Qishen Erlian Decoction combined with entecavir can not only protect liver and reduce aminotransferase, but also be antiviral and reverse liver fibrosis.
